SATURN Secretome bAsed Therapy for complex perianal fistUlas in CRohN’s disease
- Coordinator
- Everzom, France
- Runs
- 1 October 2026 to 30 September 2031
- Status
- Running
- EU funding
- €13.3m
- Total cost
- €13.3m
- Partners
- 16 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101290269
What the project is doing
In the project's own words, from its summary on CORDIS.
SATURN aims to demonstrate the safety and efficacy of EVerGel, a mesenchymal stem cell–derived extracellular vesicle–enriched secretome (MSC-EV-Se) therapy, through phase I and II clinical trials in patients with complex perianal fistulas (CPF) in Crohn’s disease. EVerGel is a dual formulation of MSC-EV-Se: a PBS solution injected subcutaneously to modulate perilesional inflammation, and injected in a thermosensitive intraluminal hydrogel to support tract closure, ensure optimal biodistribution? and provide sustained drug release.
This approach aims to improve healing in CPF refractory to anti-TNF therapies. Multicenter, randomized, placebo-controlled phase I and II clinical trials will be conducted in France, Spain, and Italy. The project addresses key bottlenecks of secretome-based therapies. A GMP-compliant, scalable, and standardized manufacturing process has already been established for clinical batches, and a potency testing matrix will be created through characterization of bioactive factors.
Longitudinal analyses of patient biopsies and fluids with multi-omics, imaging, and functional assays will map immune modulation and tissue repair pathways, offering insights into the mode of action and informing future patient stratification. To achieve these objectives, a 15-partner consortium across 5 European countries (France, Spain, Germany, Italy, and Belgium), coordinated by EVerZom (France), gathers leading clinical centers (II-FJD Madrid, ICH Milan, AP-HM Marseille), EV/secretome research labs (Université de Nantes, Univ. of Essen), manufacturing experts (EFS and INITS, France), a clinical operations network (ECRIN, France), a patient association (EFFCA, Belgium), and a regulatory CRO (Revio, Spain).
The project will deliver a standardized, regulatory-ready secretome product with initial clinical validation, interoperable assays, and reference materials, and a clear path to phase III evaluation in a high-burden indication
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Everzom | Paris | France | Coordinator |
| International Federation of Crohn's and Ulcerative Colitis Associations | Bruxelles / Brussel | Belgium | Participant |
| Universitaetsklinikum Essen | Essen | Germany | Participant |
| Fundacion Para La Gestion De La Investigacion En Salud De Sevilla | Sevilla | Spain | Third party |
| Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La Paz | Madrid | Spain | Third party |
| Fundacion Para La Investigacion De Malaga En Biomedicina Y Salud | Malaga | Spain | Third party |
| Instituto Investigacion Sanitaria Fundacion Jimenez Diaz | Madrid | Spain | Participant |
| Revio Pharmaceutical Consultants SL | Madrid | Spain | Participant |
| Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux Marseille | Marseille Cedex 20 | France | Participant |
| Centre Hospitalier Universitaire De Nantes | Nantes | France | Third party |
| Ecrin European Clinical Research Infrastructure Network | Paris | France | Participant |
| Etablissement Francais Du Sang | La Plaine Saint Denis | France | Participant |
| Inits Smo | Montpellier | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Nantes Universite | Nantes | France | Participant |
| Humanitas Mirasole SpA | Rozzano (Mi) | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI